Inclusion Criteria:

- Patients must give written informed consent to participate in this study by signing
an IRB/EC-approved Informed Consent Form (ICF) prior to admission to this study.

- Males and females, 18 years of age or older.

- Patients must have histologically proven T-cell lymphoma (TCL).

- Patients must have documented disease progression after receiving at least one prior
therapeutic regimen and must be patients for whom no known curative therapy exists.

Exclusion Criteria:

- Patient has a history of, or a concurrent, clinically significant illness, medical
condition or laboratory abnormality that, in the investigator's opinion, could affect
the conduct of the study.

- Has a B-cell lymphoma, primary CNS lymphoma, or known lymphomatous involvement of the
CNS, or any other NK/T-cell leukemia/lymphoma.

- Has uncontrolled or poorly controlled hypertension.

- Has had recent (within 1 month prior to Day 1) serious surgery or uncontrolled
infectious disease.

- Has any concurrent malignancy requiring treatment.

- Has a known positive test for Hepatitis B surface Ag, Hepatitis C, or HIV.

- Has laboratory abnormalities.

- Has difficulty swallowing or malabsorption.

- Has an ECOG performance status > 2.

- Has not recovered from adverse effects related to last prior therapy for lymphoma.

- Has had an allotransplantation within 90 days prior to Day 1 of treatment.

- Has been treated with a CYP3A4 inducer/inhibitor within 3 days prior to Day 1 of
treatment or is expected to require treatment with CYP3A4 inducer/inhibitor during
the course of the study.

- Has received systemic steroids at a dose greater than the equivalent of 10 mg/day of
prednisone within 7 days prior to Day 1 of treatment.

- Has received any other investigational therapy within 5 half-lives of the agent or 2
weeks of Day 1 of treatment, whichever is longer.

- Is a female of childbearing potential unless menopausal, surgically sterile, or
willing to use an effective method of birth control, (oral contraceptive, mechanical
barrier, long-acting hormonal agent), during the study and for 30 days thereafter.

- Is pregnant or lactating.